Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene

Journal of Medicinal Chemistry

Volumn 40, Issue 2, 1997, Pages 146-167

  Grese, Timothy A ^a   Cho, Stephen ^a   Finley, Don R ^a   Godfrey, Alexander G ^a   Jones, Charles D ^a   Lugar III, Charles W ^a   Martin, Michael J ^a   Matsumoto, Ken ^a   Pennington, Lewis D ^a   Winter, Mark A ^a   Adrian, M Dee ^a   Cole, Harlan W ^a   Magee, David E ^a   Phillips, D Lynn ^a   Rowley, Ellen R ^a   Short, Lorri L ^a   Glasebrook, Andrew L ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARYLBENZOTHIOPHENE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR STIMULATING AGENT; ESTRONE; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN ACTIVITY; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; QUALITATIVE DIAGNOSIS; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; ANIMALS; BINDING SITES; BONE AND BONES; BREAST NEOPLASMS; CELL DIVISION; CHOLESTEROL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; ORGAN SIZE; OVARIECTOMY; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 15644370745     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9606352     Document Type: Article

References (70)

1. Smith, E. P.; Boyd, J.; Frank, G. R.; Takahashi, H.; Cohen, R. M.; Specker, B.; Williams, T. C.; Lubahn, D. B.; Korach, K. S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 1994, 331, 1056-1061.
2. Ciocca, D. R.; Vargas Roig, L. M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocrinol. Rev. 1995, 16, 35-62.
3. Lindsay, R. Sex steroids in the pathogenesis and prevention of osteoporosis. In Osteoporosis: Etiology, Diagnosis, and Management; Riggs, B. L., Melton, L. J., Eds.; Raven: New York, 1988; pp 333-358.
4. Ross, R. K.; Pike, M. C.; Mack, T. M.; Henderson, B. E. Oestrogen replacement therapy and cardiovascular disease. In HRT and Osteoporosis; Drife, J. O., Studd, J. W. W., Eds.; Springer-Verlag: London, 1990; pp 209-222.
5. Cust, M. P.; Gangar, K. F.; Whitehead, M. I. Oestrogens and cancer. In HRT and Osteoporosis; Drife, J. O., Studd, J. W. W., Eds.; Springer-Verlag: London, 1990; pp 177-186.
6. Session, D. R.; Kelly, A. C.; Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertility Sterility 1993, 2, 277-284 and references therein.
7. Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.; Manson, J. E.; Stampfer, M. J.; Hennekens, C.; Rosner, B.; Speizer, F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332, 1589-1593.
8. (8) For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 37, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
9. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 37, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
10. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 37, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
11. For recent reviews, see: (a) Miquel, J.-F.; Gilbert, J. A chemical classification of nonsteroidal antagonists of sex-steroid hormone action. J. Steroid Biochem. Mol. Biol. 1988, 37, 525-544. (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens. Curr. Med. Chem. 1994, 1, 61-104. (c) Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269. (d) Jordan, V. C. Alternate antiestrogens and approaches to the prevention of breast cancer. J. Cell Biochem. 1995, 51-57.
12. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 1993, 110, 507-517.
13. (10) For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
14. For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
15. For recent reviews, see: (a) Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. Annu. Rep. Med. Chem. 1996, 31, 181-190. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539. (c) Evans, G. L.; Turner, R. T. Tissue-selective actions of estrogen analogs. Bone 1995, 17, 181S-190S.
16. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)-ethoxy] phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
17. Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 1996, 11, 835-842.
18. A portion of this work has previously appeared in communication form; see: Grese, T. A.; Cho, S.; Bryant, H. U.; Cole, H. W.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L. Synthesis and pharmacology of 2-alkyl raloxifene analogs. Bioorg. Med. Chem. Lett. 1996, 6, 201-206.
19. Jones, C. D.; Suarez, T. 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents. U.S. Patent 4,133,814.
20. Godfrey, A. G. 2-Amino-3-aroylbenzo[β]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)benzoyl]benzo[β]thio- phenes. U.S. Patent 5,420,349.
21. Ablenas, F. J.; George, B. E.; Maleki, M.; Jain, R.; Hopkinson, A. C.; Lee-Ruff, E. Destabilized carbocations. Nuclear magnetic resonance detection and reactivities of aryl α-thioformamidyl cations. Can. J. Chem. 1987, 65, 1800-1803.
22. Chippendale, K. E.; Iddon, B.; Suschitzky, H.; Taylor, D. S. Condensed thiophen ring systems. Part XV. Preparation and some reactions of 2- and 3-(secondaryamino)benzothiophens. J. Chem. Soc., Perkin Trans. I 1974, 1168-1172.
23. 3-mediated demethylation.
24. Kitching, W.; Olszowy, H.; Wauch, J.; Doddrell, D. Stereochemical aspects of substitution reactions of stannyl and germyl anionoids with cyclohexyl derivatives. J. Org. Chem. 1978, 43, 898-906.
25. (20) Gronowitz, S.; Zhang, Y.; Hörnfeldt, A.-B. Pyridine-substituted hydroxythiophenes. I. Preparation of o-(2-, 3- and 4-pyridyl)-3-hydroxythiophenes. Acta Chem. Scan. 1992, 46, 654-660. Bailey, T. R. Unsymmetrical heterobiaryl synthesis. A highly efficient palladium-catalyzed cross-coupling reaction of heteroaryl trialkylstannanes with aryl halides. Tetrahedron Lett. 1986, 27, 4407-4410. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
26. Gronowitz, S.; Zhang, Y.; Hörnfeldt, A.-B. Pyridine-substituted hydroxythiophenes. I. Preparation of o-(2-, 3- and 4-pyridyl)-3-hydroxythiophenes. Acta Chem. Scan. 1992, 46, 654-660. Bailey, T. R. Unsymmetrical heterobiaryl synthesis. A highly efficient palladium-catalyzed cross-coupling reaction of heteroaryl trialkylstannanes with aryl halides. Tetrahedron Lett. 1986, 27, 4407-4410. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
27. Gronowitz, S.; Zhang, Y.; Hörnfeldt, A.-B. Pyridine-substituted hydroxythiophenes. I. Preparation of o-(2-, 3- and 4-pyridyl)-3-hydroxythiophenes. Acta Chem. Scan. 1992, 46, 654-660. Bailey, T. R. Unsymmetrical heterobiaryl synthesis. A highly efficient palladium-catalyzed cross-coupling reaction of heteroaryl trialkylstannanes with aryl halides. Tetrahedron Lett. 1986, 27, 4407-4410. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
28. Ritter, K. Synthetic transformations of vinyl and aryl triflates. Synthesis 1993, 735-762.
29. Levin, J. I.; Turos, E.; Weinreb, S. M. An alternative procedure for the aluminum-mediated conversion of esters to amides. Synth. Commun. 1982, 12, 989-993.
30. (23) Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
31. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
32. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. Multiple binding sites for the anti-estrogen raloxifene (LY156758). J. Bone Miner. Res. 1993, 8 (Suppl. 1), S268. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617. Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and -negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
33. Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graf, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Differential growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988, 48, 6764-6768.
34. Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kauffman, R. F.; Bensch, W. R.; Frolik, C. A.; Termine, J. D.; Bryant, H. U. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 1994, 93, 63-69.
35. Bryant, H. U.; Bendele, A. M.; Magee, D. E.; Cole, H. W.; Spaethe, S. W. Pharmacologic profile of estrogen-induced uterine eosinophilia in the ovariectomized (OVX) rat. Pharmacologist 1992, 34, 194.
36. Wronski, T. J.; Yen, C.-F. The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Mater. 1991, Suppl. 1, 69.
37. Haehnel, R.; Twaddle, E.; Ratajczak, T. Specificity of the estrogen receptor of human uterus. J. Steroid Biochem. 1973, 4, 21-31.
38. Anstead, G. M.; Wilson, S. R.; Katzenellenbogen, J. A. 2-Arylindenes and 2-arylindenones: molecular structures and considerations in the binding orientation of unsymmetrical nonsteroidal ligands to the estrogen receptor. J. Med. Chem. 1989, 32, 2163-2171.
39. Lovely, C. J.; Gilbert, N. E.; Liberto, M. M.; Sharp, D. W.; Lin, Y. C.; Brueggemeier, R. W. 2-(Hydroxyalkyl)estradiols: Synthesis and biological evaluation. J. Med. Chem. 1996, 39, 1917-1923.
40. Anstead, G. M.; Peterson, C. S.; Pinney, K. G.; Wilson, S. R.; Katzenellenbogen, J. A. Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen receptor ligands. J. Med. Chem. 1990, 33, 2726-2734.
41. (a) Fuchs-Young, R.; Magee, D. E.; Cole, H. W.; Short, L.; Glasebrook, A. L.; Rippy, M. K.; Termine, J. D.; Bryant, H. U. Raloxifene is a tissue specific anti-estrogen that blocks tamoxifen or estrogen-stimulated uterotrophic effects. Endocrinology 1995, 135 (Suppl.), 57.
42. (b) Bryant, H. U.; Wilson, P. K.; Adrian, M. D.; Cole, H. W.; Short, L. L.; Dodge, J. A.; Grese, T. A.; Sluka, J. P.; Glasebrook, A. L. Selective estrogen receptor modulators: Pharmacological profile in the rat uterus. J. Soc. Gynecol. Invest. 1996, 3 (Suppl.), 152A.
43. For example, tamoxifen stimulates a dose dependent increase in uterine wet weight as well as increases in other measures of uterine stimulation such as epithelial cell height (ref 34). Although raloxifene also stimulates a modest increase in uterine wet weight, this increase is not dose related and is not coincident with increases in other measures of uterine hypertrophy such as epithelial cell height and total estrogenicity. This uterine weight increase has therefore been attributed to water retention (ref 25).
44. The utility of EPO activity as a surrogate for other measures of uterine stimulation induced by structurally diverse ER modulators has been previously demonstrated; see: Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10, 905-912.
45. (a) Peters, R. H.; Crowe, D. F.; Avery, M. A.; Chong, W. K. M.; Tanabe, M. 17-Desoxy estrogen analogues. J. Med. Chem. 1989, 32, 1642-1652 and references therein.
46. (b) Omar, A. M. M. E.; Ahmed, I. C.; AboulWafa, O. M.; Hassan, A. M.; Ismail, K. A.; El-Din, M. M. M.; Mansour, N. A. Synthesis, binding affinities and uterotrophic activity of some 2-substituted estradiol and ring-A-fused pyrone derivatives. Eur. J. Med. Chem. 1994, 29, 25-32.
47. However, some derivatives which do not bind the ER may be activated metabolically and still demonstrate the SERM profile in vivo. See discussion vide supra.
48. Kauffman, R. F.; Bensch, W. R.; Roudebush, R. E.; Cole, H. W.; Bean, J. S.; Phillips, D. L.; Monroe, A.; Cullinan, G. J.; Glasebrook, A. L.; Bryant, H. U. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator (SERM). J. Pharmacol. Exp. Ther., submitted for publication.
49. (a) Weiss, D. J.; Gurpide, E. Non-genomic effects of estrogens and antiestrogens. J. Steroid Biochem. 1988, 31, 671-676.
50. (b) Hendry, L. B.; Chu, C. K.; Rosser, M. L.; Copland, J. A.; Wood, J. C.; Mahesh, V. B. Design of novel antiestrogens. J. Steroid Biochem. Mol. Biol. 1994, 49, 269-280.
51. (c) Colletta, A. A.; Benson, J. R.; Baum, M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res. Treat. 1994, 31, 5-9.
52. (d) Cypriani, B.; Tabacik, C.; Descomps, B. Effect of estradiol and antiestrogens on cholesterol biosynthesis in hormone-dependent and -independent breast cancer cell lines. Biochim. Biophys. Acta 1988, 972, 167-178.
53. (e) Hardcastle, I. R.; Rowlands, M. G.; Jarman, M. Antiestrogens as calmodulin antagonists. Curr. Med. Chem. 1996, 3, 211-226.
54. (a) McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
55. (b) Klinge, C. M.; Traish, A. M.; Driscoll, M. D.; Hilf, R.; Bambara, R. A. Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro. Steroids 1996, 61, 278-289.
56. For a detailed description of the current understanding of tissue-specific steroid hormone activities, see: Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
57. McDonnell, D. P.; Dana, S. L.; Hoener, P. A.; Lieberman, B. A.; Imhof, M. O.; Stein, R. B. Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor. Ann. N. Y. Acad. Sci. 1995, 761, 121-137.
58. A candidate gene which may be responsible for the bone effects of estradiol and raloxifene has recently been identified; see: (a) Yang N N.; Bryant, H. U.; Hardikar, S.; Sato, M.; Galvin, R. J. S.; Glasebrook, A. L.; Termine, J. D. Estrogen and raloxifene stimulate transforming growth factor-β3 gene espression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 1996, 137, 2075-2084.
59. (b) Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996, 273, 1222-1225.
60. Kuiper, G. G. J. M.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930.
61. (a) Baker, K. V.; Brown, J. M.; Hughes, N.; Skarnulis, A. J.; Sexton, A. Mechanical activation of magnesium turnings for the preparation of reactive Grignard reagents. J. Org. Chem. 1991, 56, 698-703 and references therein.
62. (b) Jayasuriya, N.; Kagan, J. The synthesis of bithienyls and terthienyls by nickel-catalyzed coupling of Grignard reagents. Heterocycles 1986, 24, 2261-2264.
63. Corey, E. J.; Venkateswarlu, S. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.
64. 6 with NaOD induced a similar upfield shift for the protons assigned to the 3′-position of the 2-aryl ring.
65. Highet, R. J.; Highet, P. F. The characterization of complex phenols by nuclear magnetic resonance spectra. J. Org. Chem. 1965, 30, 902-906.
66. Konishi, H.; Aritomi, K.; Okano, T.; Kiji, J. A mild selective monobromination reagent system for alkoxybenzenes; N-bromosuccinimide-silica gel. Bull Chem. Soc. Jpn. 1989, 62, 591-593.
67. White, S. R.; Kulp, V. P.; Spaethe, S. M.; VanAlstyne, E. L.; Leff, A. R. A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media. J. Immunol. Med. 1991, 44, 257-263.
68. Wiebe, D. A.; Bernert, J. T. Influence of incomplete cholesterylester hydrolysis on enzymatic measurements of cholesterol. Clin. Chem. 1984, 19, 476-482.
69. Frolik, C. A.; Bryant, H. U.; Black, E. C.; Magee, D. E.; Chandrasekhar, S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996, 18, 621-627.
70. Sato, M.; Kim, J.; Short, L. L.; Slemenda, C. W.; Bryant, H. U. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 1995, 272, 1252-1259.